Skip to main content
Sign In

Welcome to the Barbara Davis Center for Diabetes at the University of Colorado School of Medicine on the Anschutz Medical Campus in Aurora, Colorado.

Barbara Davis Center Banner Image


Women, insulin and sex hormones


This study plans to learn more about the menstrual cycle and heart disease in women with type 1 diabetes compared to women who do not have diabetes. It involves 5 study visits-- a screening visit and 4 visits that span a menstrual cycle-- at the Barbara Davis Center. The screening visit is to ensure eligibility in the study. The first menstrual cycle visit is a fasting visit that will take 1½ to 2 hours at the beginning of your cycle. The final 3 visits are non fasting blood draws that span the rest of the menstrual cycle. Additionally, a continuous glucose monitor is inserted at the first and third menstrual cycle visits and is worn for 7 days at a time. Up to 180 people from the Denver area will participate in this study.

You may be eligible if you are:

  • Age 18-40 and premenopausal
  • Not currently using hormones (oral contraceptives, contraceptive patch, norplant, Depo-Provera, post-menopausal hormones)
  • Not currently pregnant or planning to become pregnant in the next 3 months
  • No recent history of amenorrhea (no menstrual period for at least 3 months)
  • Menstrual cycle between 25-35 days on average
  • Normal thyroid function (can be treated)
  • Diagnosed with type 1 diabetes for at least 5 years
  • Put on insulin within a year of diagnosis and on current insulin therapy
  • HbA1c < 9.5
  • Normal kidney function (urinary albumin excretion rate < 200 µg/min)

There is an additional insulin sensitivity study which is optional, and involves an overnight stay at University Hospital and a metabolic study from 7 am – 3pm.

Compensation is provided for all study visits.

For more information or to schedule a screening visit, please contact:

Talia Brown, Research Assistant 303-724-7506
Rachel Sippl, Research Assistant 303-724-7505
Janet Snell-Bergeon, Principal Investigator 303-724-6762
E-mail us at